Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Tau Pharmaceuticals, a US based, wholly owned subsidiary of the Sigma-Tau Group, has announced that the European Commission has granted an orphan drug designation for Artesunate for the treatment of malaria.
Subscribe to our email newsletter
Sigma-Tau is developing this product as an emergency treatment for severe and complicated malaria in collaboration with the Walter Reed Army Institute of Research.
Gregg Lapointe, Sigma-Tau Pharmaceutical’s COO, said: “We commend the European Commission for granting orphan drug designation to Artesunate. The designation reinforces Sigma-Tau’s commitment to the development of new medicines for neglected diseases.”